Evidence map›Paper›PMID 40060344›Full record

ReviewSouth Asian journal of cancer2024

Adjuvant Chemotherapy in Colon Cancer: Simple is Better… Less is More.

Prasad Narayanan, Shyam Aggarwal, Manish Singhal, Vamshi Krishna, A K Rathi, Brig H P Singh, Atul Sharma, J B Sharma, Amit Bhargava, P Suresh and 10 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in South Asian journal of cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Prasad NarayananDepartment of Medical Oncology, Cytecare Hospital, Bengaluru, Karnataka, India.
Shyam AggarwalDepartment of Medical Oncology, Sir Ganga Ram Hospital, New Delhi, India.
Manish SinghalDepartment of Medical Oncology, Indraprastha Apollo Hospital, New Delhi, India.
Vamshi KrishnaDepartment of Medical Oncology, AIG Hospital, Hyderabad, Telangana, India.
A K RathiDepartment of Radiation Oncology, Lok Nayak Hospital, New Delhi, India.
Brig H P SinghDepartment of Medical Oncology, Park Hospital, Mohali, Punjab, India.
Atul SharmaDepartment of Medical Oncology, Max Superspeciality Hospital, New Delhi, India.
J B SharmaDepartment of Medical Oncology, Action Cancer Hospital, New Delhi, India.
Amit BhargavaDepartment of Medical Oncology, Fortis Hospital, New Delhi, India.
P SureshDepartment of Medical Oncology, Army Hospital RR, New Delhi, India.
Meenu WaliaDepartment of Medical Oncology, Max Superspeciality Hospital, New Delhi, India.
H S DarlingDepartment of Medical Oncology, Air Force Hospital, Jorhat, Assam, India.
K MedhiDepartment of Medical Oncology, Batra Hospital, New Delhi, India.
Kumardeep DuttaDepartment of Medical Oncology, Max Superspeciality Hospital, New Delhi, India.
Sajjan Singh RajpurohitDepartment of Medical Oncology, BLK Max Superspeciality Hospital, New Delhi, India.
Prashant MehtaDepartment of Medical Oncology, Amrita Hospital, Faridabad, Haryana, India.
Vikas GoswamiDepartment of Medical Oncology, Max Superspeciality Hospital, New Delhi, India.
Saumitra RawatDepartment of Surgical Gastroenterology, Sir Ganga Ram Hospital, New Delhi, India.
C SelvasekarClinical Services & Specialist Surgery, The Christie NHS Foundation Trust, Manchester, United Kingdom.
Purvish M ParikhDepartment of Clinical Hematology, Sri Ram Cancer Center, Mahatma Gandhi University of Medical Sciences and Technology, Jaipur, Rajasthan, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A significant number of patients with colorectal cancer (CRC) benefit from adjuvant therapy. While 6 months of FOLFOX is standard of care, newer regimens like CAPOX and SOX allow for shorter durations. Trials of importance include SCOT (U.K., Denmark, Spain, Sweden, Australia, New Zealand), TOSCA (Italy), Alliance/SWOG80702 (U.S., Canada), IDEA (France), ACHIEVE (Japan), and HORG (Greece). Management recommendation is also based on patient preferences, dividing them into fighters and fatalists. Better patient selection is possible with the use of novel molecular-based biomarkers and circulating tumor deoxyribonucleic acid monitoring of minimal residual disease. There also needs to be special consideration for the geriatric patients-especially due to their limited mobility, comorbidities, and polypharmacy.

Indexed as

ctDNAdrug metabolismgeriatric patientsMRDoverall survivaltoxicity

Identifiers

PMID40060344
PMCPMC11888808

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.